Efficacy and Safety in Clinical Practice of Ombitasvir/Paritaprevir/ Ritonavir and Dasabuvir Administered for 8 Weeks (3D8) in Treatment-naïve Genotype 1b Hepatitis C Virus Infected Patients: Analysis of Data From Hepa-C Registry
Phase of Trial: Phase IV
Latest Information Update: 28 May 2018
Price : $35 *
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 18 May 2018 Status changed from recruiting to completed.
- 14 Apr 2018 Preliminary results presented at The International Liver Congress 2018.
- 24 Oct 2017 Preliminary results assessing the efficacy and safety of 3D8 in a real-world cohort of genotype 1b infected treatment-naive patients with mild-moderate fibrosis (F0-2) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases